Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45% vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Heparin binds to antithrombin III, causing a conformational change that accelerates the inhibition of thrombin (factor IIa) and activated factor X (factor Xa), and to a lesser extent factors IXa, XIa, and XIIa, thereby preventing thrombus formation and extension.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
Prophylaxis and treatment of venous thrombosis and pulmonary embolism,Treatment of atrial fibrillation with embolization,Prophylaxis and treatment of peripheral arterial embolism,Anticoagulant use in extracorporeal circulation (e.g., during hemodialysis, cardiopulmonary bypass),Unstable angina and non-ST-segment elevation myocardial infarction (off-label),Acute coronary syndromes (off-label)
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
IV: Initial bolus of 80 units/kg, then 18 units/kg/hour continuous infusion. Adjust based on a PTT. Typical maintenance: 1300 units/hour for adult (70 kg).
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
Mean 1-2 hours (dose-dependent: increases with dose due to saturable clearance; at 100 U/kg IV: ~1 hr; at 400 U/kg: ~2.5 hrs); clinical context: may be prolonged in hepatic/renal disease
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Heparin is metabolized by the liver and reticuloendothelial system. It is partially desulfated and depolymerized; some components are excreted unchanged in urine. Metabolism is dose-dependent and saturable at high doses.
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Renal (primarily via saturable mechanism; small amount metabolized by liver and reticuloendothelial system; no biliary/fecal elimination of significance)
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
Very high, ~95-98% (binds to antithrombin III, albumin, and other plasma proteins)
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
0.05-0.1 L/kg (confined to plasma volume; low Vd due to high protein binding and large molecular size)
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
SC: 20-30% (variable based on injection site and depth); IV: 100%
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
No specific GFR-based dose adjustment required; monitor a PTT and adjust accordingly. Accumulation not significant due to large molecular weight and extensive protein binding.
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
No specific Child-Pugh based modifications. Heparin clearance may be reduced in severe hepatic impairment; monitor coagulation parameters closely.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
IV: Bolus 75-100 units/kg over 10 minutes, then continuous infusion: Infants: 28 units/kg/hour; Children >1 year: 20 units/kg/hour; Adolescents: 18 units/kg/hour. Titrate to target a PTT (usually 60-85 seconds).
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
Elderly patients (≥65 years) may have reduced heparin clearance; use lower initial infusion rates (e.g., 15 units/kg/hour) and monitor a PTT frequently to avoid over-anticoagulation.
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
Heparin is not intended for intramuscular use. There is an increased risk of bleeding complications. Monitor platelet counts regularly; heparin-induced thrombocytopenia (HIT) can occur. Use with caution in patients with history of HIT. Preservative-free heparin should be used in neonates and infants.
None
Monitor for signs of bleeding (hematuria, melena, easy bruising, epistaxis, etc.),Heparin-induced thrombocytopenia (HIT) and heparin-induced thrombocytopenia with thrombosis (HITTS): discontinue heparin immediately if HIT suspected,Epidural or spinal catheter use: risk of spinal or epidural hematoma with concurrent anticoagulants,Hyperkalemia due to aldosterone suppression (especially in elderly, diabetic, renally impaired),Osteoporosis with prolonged use (>1 month),Hypersensitivity reactions including urticaria, angioedema, anaphylaxis
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Hypersensitivity to heparin or any component,History of heparin-induced thrombocytopenia (HIT) or HITTS,Active major bleeding (e.g., GI bleeding, intracranial hemorrhage),Severe thrombocytopenia (platelet count <100,000/mm³),Use of intramuscular injections while on heparin,Uncontrollable bleeding diathesis (e.g., hemophilia, severe liver disease)
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
No significant food interactions. However, avoid excessive intake of foods high in vitamin K (e.g., leafy green vegetables, broccoli, Brussels sprouts) unless consistent consumption pattern is maintained, as vitamin K can antagonize heparin's effect indirectly. Alcohol may increase bleeding risk and should be limited.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
Heparin does not cross the placenta and is not teratogenic. No increased risk of fetal malformations reported. Risk of hemorrhage at delivery.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
Heparin is not excreted into breast milk due to high molecular weight. Compatible with breastfeeding. M/P ratio not applicable (not measurable).
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
Pharmacokinetic changes in pregnancy (increased plasma volume, renal clearance) may require higher doses to achieve therapeutic a PTT. Dose adjustment based on a PTT monitoring advised.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
Heparin sodium 10,000 units in 0.45% sodium chloride is a high-concentration infusion typically used for continuous intravenous administration in acute thrombotic events or prophylaxis. Confirm compatibility with all IV lines and medications; avoid concurrent use with other anticoagulants without clear indication. Monitor a PTT closely, targeting 1.5-2.5 times control for therapeutic effect. Rapid reversal requires protamine sulfate (1 mg per 100 units heparin). Use with caution in renal impairment, elderly, and patients with history of heparin-induced thrombocytopenia (HIT). Check platelet counts every 2-3 days to detect HIT early. Weight-based dosing is standard; this formulation is often used for bolus administration or infusion in fluid-restricted patients.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
You will receive this medication through an IV line to prevent or treat blood clots.,You may experience bruising or bleeding more easily; report any unusual bleeding, dark stools, or blood in urine immediately.,Avoid taking aspirin, ibuprofen, or other NSAIDs unless prescribed by your doctor, as they increase bleeding risk.,Inform all healthcare providers (including dentists) that you are taking heparin.,Do not discontinue the medication suddenly; it will be tapered as directed by your doctor.,You may be required to have regular blood tests (a PTT, platelet count) to monitor the drug's effect.,Notify your doctor immediately if you develop chest pain, shortness of breath, or signs of allergic reaction (rash, difficulty breathing).
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45% vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Heparin binds to antithrombin III, causing a conformational change that accelerates the inhibition of thrombin (factor IIa) and activated factor X (factor Xa), and to a lesser extent factors IXa, XIa, and XIIa, thereby preventing thrombus formation and extension.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45% and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45% is: IV: Initial bolus of 80 units/kg, then 18 units/kg/hour continuous infusion. Adjust based on a PTT. Typical maintenance: 1300 units/hour for adult (70 kg).. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45% and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45% is classified as Category A/B. Heparin does not cross the placenta and is not teratogenic. No increased risk of fetal malformations reported. Risk of hemorrhage at delivery.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.